In the last 3 years, revelations linking gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) have had a tremendous impact on the utilization of enhanced magnetic resonance imaging (MRI) in patients with kidney disease. Virtually unknown to the radiology community prior to 2006, NSF has generated significant concern and confusion among radiologists, clinicians and patients.
|Original language||English (US)|
|Number of pages||12|
|State||Published - Apr 1 2009|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging